Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136373

Published: 2020

Journal Articles

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Neil Beeharry, Sean Landrette, PhD, Jeff Grotzke, PhD, Sophia Gayle, PhD, Marylens Hernandez, PhD, Stephanie Halene, MD, Peter R Young, PhD, Langdon L Miller, MD, Tian Xu, PhD, Jonathan Rothberg, PhD, Henri Lichenstein, PhD

Blood (2019) 134 (Supplement_1): 2664.

https://doi.org/10.1182/blood-2019-125770

Published: 2019

Journal Articles

A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies

Ajay K. Gopal, MD, Rod Ramchandren, MD, Nashat Y. Gabrail, Manish R Patel, MD, Ding Wang, MDPhD, Langdon L Miller, MD, Vikas Goel, PhD, Gary G Chiang, PhD, Kevin R Webster, PhD, Sam Sperry, PhD, Debra T Vallner, PhDMBA, Cara Casseday, BSc MBA, Jeremy Barton, MBBS

Blood (2017) 130 (Supplement 1): 4624.

https://doi.org/10.1182/blood.V130.Suppl_1.4624.4624

Published: 2017

Journal Articles

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

Wael A Harb, MD, Catherine S Diefenbach, MD, Nehal Lakhani, MD PhD, Sarah C Rutherford, MD, Marshall T Schreeder, MD, Stephen M Ansell, MD PhD, Taimur Sher, MD, David M Aboulafia, MD, Jonathon B Cohen, MDMS, Darrell Nix, BS, PhD, Sean Landrette, PhD, Kate Flanders, BS, Langdon L Miller, MD, Henri Lichenstein, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017) 130 (Supplement 1): 4119.

https://doi.org/10.1182/blood.V130.Suppl_1.4119.4119

Published: 2017

Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD

Blood (2016) 128 (22): 2032.

https://doi.org/10.1182/blood.V128.22.2032.2032

Published: 2016

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2013) 122 (21): LBA-6.

https://doi.org/10.1182/blood.V122.21.LBA-6.LBA-6

Published: 2013

Journal Articles

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Steven E. Coutre, MD, John P. Leonard, MD, Richard R. Furman, MD, Jacqueline C. Barrientos, MD, Sven de Vos, MD, PhD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Thomas E. Boyd, MD, Nathan H Fowler, MD, Leanne M. Holes, Brian J. Lannutti, PhD, Dave M. Johnson, Langdon L Miller, MD, Thomas M. Jahn, MD/PhD

Blood (2012) 120 (21): 191.

https://doi.org/10.1182/blood.V120.21.191.191

Published: 2012

Journal Articles

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Nathan H Fowler, MD, Sven de Vos, MD, PhD, Marshall T. Schreeder, MD, John P. Leonard, MD, Ian W. Flinn, MD, PhD, Steve Coutre, MD, Nina D. Wagner-Johnston, MD, Jeff Sharman, MD, Ralph V. Boccia, MD, Jacqueline C. Barrientos, MD, Thomas E. Boyd, MD, Leanne M. Holes, Brian J. Lannutti, PhD, David Johnson, Thomas M. Jahn, MD/PhD, Langdon L Miller, MD, Wayne R Godfrey, MD

Blood (2012) 120 (21): 3645.

https://doi.org/10.1182/blood.V120.21.3645.3645

Published: 2012

Journal Articles

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Heather K Webb, Ph.D., Hao Chen, Ph.D., Albert S Yu, M.D., Sissy Peterman, Leanne Holes, Brian Lannutti, PhD, Langdon L. Miller, MD, Roger G Ulrich, Ph.D.

Blood (2010) 116 (21): 1774.

https://doi.org/10.1182/blood.V116.21.1774.1774

Published: 2010

NARROW

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

A Phase 1-2 Dose-Escalation and Cohort- Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies

Phase 1 Clinical Safety, Pharmacokinetics (PK), and Activity of Apilimod Dimesylate (LAM-002A), a First-in-Class Inhibitor of Phosphatidylinositol-3-Phosphate 5-Kinase (PIKfyve), in Patients with Relapsed or Refractory B-Cell Malignancies

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only